Integra Lifesciences Holdings Corp income statement

In fiscal 2025, Integra Lifesciences Holdings Corp reported revenue of $1.64bn, up 1.5% on the year before, operating income of −$493m (a -30.2% margin) and net income of −$516m, or −$6.74 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Integra Lifesciences Holdings Corp: income statement, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Revenue	682	732	780	831	697	797	883	992	1,188	1,472	1,518	1,372	1,542	1,558	1,542	1,611	1,635	1,657
Cost of revenue	—	—	—	—	—	—	—	349	436	571	565	521	598	587	657	728	804	789
Gross profit	—	—	—	—	—	494	556	643	753	901	953	851	945	970	885	882	832	867
Research and development	44	48	51	51	43	44	51	58	63	78	80	77	93	101	104	115	99	94
Selling, general and administrative	281	305	358	373	332	376	416	456	624	691	688	595	637	616	657	717	700	685
Operating income	98	99	55	74	35	68	80	115	45	111	94	151	197	239	112	28	−493	73
Interest expense	23	18	28	22	20	22	24	26	35	65	54	72	50	50	51	71	86	92
Income before tax	73	82	28	52	19	46	61	90	11	57	60	94	215	214	81	−18	−564	22
Income tax	22	16	1	11	−3	9	54	16	−53	−3	10	−40	46	33	13	−11	−47	9
Net income	51	66	28	41	−21	34	−4	75	65	61	50	134	169	181	68	−7	−516	13
Diluted EPS	$0.87	$1.08	$0.47	$0.72	−$0.37	$0.52	−$0.05	$0.94	$0.82	$0.72	$0.58	$1.57	$1.98	$2.16	$0.84	−$0.09	−$6.74	$0.17
Diluted shares (average)	59m	60m	59m	57m	58m	66m	71m	79m	79m	84m	86m	85m	85m	84m	80m	77m	77m	78m
EBITDA	138	138	105	126	66	114	138	188	134	222	203	193	237	279	152	71	−449	—

US$ millions unless shown otherwise. Fiscal quarters.

Integra Lifesciences Holdings Corp: income statement, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Revenue	443	383	416	402	435	392	419	411
Cost of revenue	194	188	206	195	214	175	199	201
Gross profit	249	194	209	207	221	217	220	210
Research and development	31	25	27	22	25	24	24	22
Selling, general and administrative	179	181	180	169	169	178	172	165
Operating income	36	−15	−513	12	23	11	19	19
Interest expense	19	19	21	23	24	22	23	23
Income before tax	23	−30	−531	−7	4	−2	5	16
Income tax	3	−5	−47	−1	6	2	0	1
Net income	19	−25	−484	−5	−2	−5	4	15
Diluted EPS	$0.25	−$0.33	−$6.31	−$0.07	−$0.02	−$0.06	$0.06	$0.19

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: IART vs MMSI IART vs PEN IART vs ITGR

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Integra Lifesciences Holdings Corp's SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Integra Lifesciences Holdings Corp.